retatrutide dosage calculator female weight loss Retatrutide Dose Escalation Chart &

doi:10.1007/s40279-015-0385-9 This Proof Points edition was originally published on LinkedIn on 2/22/24.

It focuses on GIP and GLP-1 pathways to help manage appetite, the amount we eat, and blood sugar levels

It is widely seen as the natural successor to tirzepatide in the same lab

If you're currently on a prescription GLP-1 injection and you're thinking about switching, please speak to your healthcare provider first

Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), has announced positive topline results from a phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes

Store credit: Available upon approval for future purchases